PTEN and endometrial cancer: We first employed the newly developed CRISPR/Cas9 system to deplete PTEN in Hec-1A cells (an endometrioid endometrial cancer cell line with intact PTEN, PTEN-WT), and named them PTEN-KO cells thereafter (Supplementary Figures 4a and b).